Soleiman Kheiri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Soleiman Kheiri has a total of 190 co-authors. Here are the top co-authors by number of shared publications:
- Ali Momeni
Internal Medicine Department, Shahrekord University of Medical Sciences, Shahrekord, Iran
6 shared publications - Abolfazl Khoshdel
Clinical Biochemistry Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran
5 shared publications - Mahmoud Rafieian-Kopaei
Medical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran
5 shared publications - Hamid Nasri
Department of Natural Sciences, The University of Georgia, Tbilisi, Georgia
4 shared publications - Morteza Hashemzadeh-Chaleshtori
Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran
4 shared publications - Reza Masoudi
Department of Medical-Surgical Nursing, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 shared publications
Latest Publications
- Open Access
- 14 November 2026
- Published by Springer Nature in BMC Complementary Medicine and Therapies
Date palm pollen supplementation and sexual health in postmenopausal women: a double-blind randomized placebo-controlled trial
- 14 November 2026
- Published by Springer Nature in BMC Complementary Medicine and Therapies
Open AccessDate palm pollen supplementation and sexual health in postmenopausal women: a double-blind randomized placebo-controlled trial
- Open Access
- 4 September 2026
- Published by Springer Nature in BMC Psychology
Relationship between common non-communicable diseases (NCDs), risk factors and happiness in Shahrekord PERSIAN Cohort Study: a path analysis model in Iran
- 4 September 2026
- Published by Springer Nature in BMC Psychology
Open AccessRelationship between common non-communicable diseases (NCDs), risk factors and happiness in Shahrekord PERSIAN Cohort Study: a path analysis model in Iran
- 2 July 2026
- Published by Bentham Science Publishers Ltd. in Current Bioactive Compounds
- Vol. 22, 1-8
Efficacy of Bunium persicum Extract for Infantile Colic: A Randomized Controlled Trial
Introduction/Objective: Due to the presence of anti-spasmodic and anti-inflammatory compounds in plant extracts, recent attention has been paid to using these traditional compounds to treat infantile colic. This study aimed to evaluate the beneficial effects of Bunium persicum extract in improving infantile colic. Methods: In this double-blind clinical trial, infants with colic were randomly assigned to receive 0.5 mL of B. persicum extract daily as drops for 2 weeks, along with a relaxation technique, or to receive only relaxation techniques as the control. The symptoms related to infantile colic were evaluated on the first, seventh, and fourteenth days after therapeutic interventions. Data were analyzed by SPSS version 22. Results: The duration of crying, frequency of crying, and duration of restlessness were significantly reduced in the intervention group compared with the control group on the fourteenth day after the therapeutic intervention (p 0.05). Discussion: B. persicum extract reduced crying and restlessness in colicky infants, supporting its antispasmodic role. No effect was seen on sleep or defecation. Small sample size and short follow-up limit generalization; larger, long-term studies are needed Conclusion: The extract of B. persicum can be very effective in improving infantile colic, and thus it can be considered as a valuable therapeutic supplement in the treatment of this infantile complication
- 2 July 2026
- Published by Bentham Science Publishers Ltd. in Current Bioactive Compounds
- Vol. 22, 1-8
Efficacy of Bunium persicum Extract for Infantile Colic: A Randomized Controlled Trial
Introduction/Objective: Due to the presence of anti-spasmodic and anti-inflammatory compounds in plant extracts, recent attention has been paid to using these traditional compounds to treat infantile colic. This study aimed to evaluate the beneficial effects of Bunium persicum extract in improving infantile colic. Methods: In this double-blind clinical trial, infants with colic were randomly assigned to receive 0.5 mL of B. persicum extract daily as drops for 2 weeks, along with a relaxation technique, or to receive only relaxation techniques as the control. The symptoms related to infantile colic were evaluated on the first, seventh, and fourteenth days after therapeutic interventions. Data were analyzed by SPSS version 22. Results: The duration of crying, frequency of crying, and duration of restlessness were significantly reduced in the intervention group compared with the control group on the fourteenth day after the therapeutic intervention (p 0.05). Discussion: B. persicum extract reduced crying and restlessness in colicky infants, supporting its antispasmodic role. No effect was seen on sleep or defecation. Small sample size and short follow-up limit generalization; larger, long-term studies are needed Conclusion: The extract of B. persicum can be very effective in improving infantile colic, and thus it can be considered as a valuable therapeutic supplement in the treatment of this infantile complication
- 1 July 2026
- Published by Bentham Science Publishers Ltd. in The Natural Products Journal
- Vol. 16 (6) , 1-8
The Therapeutic Impact of Cocoa Powder on the Improvement of Childhood Acute Non-inflammatory Diarrhea: A Randomized Clinical Trial
Introduction: Cocoa powder potentially has antiviral, anti-inflammatory, and antioxidant effects. We aimed to evaluate its impact on the treatment of acute non-inflammatory diarrhea in children. Methods: This randomized double-blinded clinical trial were performed on children aged 1 to 6 years with acute non-inflammatory diarrhea. The children were randomly assigned to receive routine diarrhea treatment plus a cocoa powder solution (n = 69) or routine diarrhea treatment alone (n = 69). Gastrointestinal symptoms as well as time of improvement and length of hospitalization were assessed and compared at the end of interventions. Analyses were done using SPSS, and p<0.05 was significant. Results: The mean length of hospitalization and the mean recovery time in the intervention group were significantly shorter than in the control group (p<0.01). Patients in the intervention group experienced a higher frequency of defecation after the intervention as compared to the control group (p<0.01). The mean Bristol score was also significantly lower in the intervention group than in the placebo group (p0.05). Discussion: The results support that cocoa powder can be used as a complementary medicine in children with acute non-inflammatory diarrhea, consistent with prior evidence on its anti-diarrheal properties. However, larger, multi-center trials are needed to confirm efficacy and explore underlying mechanisms. Conclusion: Cocoa powder can be effective in improving acute non-inflammatory diarrhea in children aged 1 to 6 years.
- 1 July 2026
- Published by Bentham Science Publishers Ltd. in The Natural Products Journal
- Vol. 16 (6) , 1-8
The Therapeutic Impact of Cocoa Powder on the Improvement of Childhood Acute Non-inflammatory Diarrhea: A Randomized Clinical Trial
Introduction: Cocoa powder potentially has antiviral, anti-inflammatory, and antioxidant effects. We aimed to evaluate its impact on the treatment of acute non-inflammatory diarrhea in children. Methods: This randomized double-blinded clinical trial were performed on children aged 1 to 6 years with acute non-inflammatory diarrhea. The children were randomly assigned to receive routine diarrhea treatment plus a cocoa powder solution (n = 69) or routine diarrhea treatment alone (n = 69). Gastrointestinal symptoms as well as time of improvement and length of hospitalization were assessed and compared at the end of interventions. Analyses were done using SPSS, and p<0.05 was significant. Results: The mean length of hospitalization and the mean recovery time in the intervention group were significantly shorter than in the control group (p<0.01). Patients in the intervention group experienced a higher frequency of defecation after the intervention as compared to the control group (p<0.01). The mean Bristol score was also significantly lower in the intervention group than in the placebo group (p0.05). Discussion: The results support that cocoa powder can be used as a complementary medicine in children with acute non-inflammatory diarrhea, consistent with prior evidence on its anti-diarrheal properties. However, larger, multi-center trials are needed to confirm efficacy and explore underlying mechanisms. Conclusion: Cocoa powder can be effective in improving acute non-inflammatory diarrhea in children aged 1 to 6 years.
- 20 April 2026
- Published by Bentham Science Publishers Ltd. in Recent Advances in Inflammation & Allergy Drug Discovery
- Vol. 20, 1-8
The Association of Persistent Fecal White Blood Cell Excretion with Impaired Weight Gain and Food Allergy Among Children with Allergic Proctocolitis
Introduction/Objective: In children affected by allergic proctocolitis, impaired weight gain and developmental failure to thrive can be a prominent manifestation. However, it remains unclear whether the association between White Blood Cell (WBC) excretion in these patients and the occurrence of food allergies is associated with subsequent impaired weight gain after the start of complementary feeding. Materials and Methods: In this prospective cohort study, 85 children with allergic proctocolitis were followed from birth to 1 year of age regarding continued WBC excretion, weight gain, and the presence or absence of allergic symptoms. Also, the weight gain of children was examined and compared between those with continued leukocyte excretion and those without. Data were analyzed using SPSS statistical software version 26. Results: The age distribution of infants in the two groups with and without persistent WBC excretion did not differ significantly (p =0.35). However, the gender distribution was significantly different, with persistent excretion higher in boys (p =0.023). Examination of standardized weight changes showed no significant difference between the two groups, with and without persistent WBC excretion (p >0.05). Discussion: Persistent leukocyte excretion did not affect weight gain, consistent with reports that inflammatory stool markers have limited predictive value in allergic proctocolitis. Future studies with larger samples and refined inflammatory biomarkers are needed to clarify the clinical significance and potential long-term allergic implications of persistent intestinal inflammation. Conclusion: Persistent WBC excretion in children with allergic proctocolitis was observed in some of the patients, but was not associated with impaired weight gain during the first year of life.
- 20 April 2026
- Published by Bentham Science Publishers Ltd. in Recent Advances in Inflammation & Allergy Drug Discovery
- Vol. 20, 1-8
The Association of Persistent Fecal White Blood Cell Excretion with Impaired Weight Gain and Food Allergy Among Children with Allergic Proctocolitis
Introduction/Objective: In children affected by allergic proctocolitis, impaired weight gain and developmental failure to thrive can be a prominent manifestation. However, it remains unclear whether the association between White Blood Cell (WBC) excretion in these patients and the occurrence of food allergies is associated with subsequent impaired weight gain after the start of complementary feeding. Materials and Methods: In this prospective cohort study, 85 children with allergic proctocolitis were followed from birth to 1 year of age regarding continued WBC excretion, weight gain, and the presence or absence of allergic symptoms. Also, the weight gain of children was examined and compared between those with continued leukocyte excretion and those without. Data were analyzed using SPSS statistical software version 26. Results: The age distribution of infants in the two groups with and without persistent WBC excretion did not differ significantly (p =0.35). However, the gender distribution was significantly different, with persistent excretion higher in boys (p =0.023). Examination of standardized weight changes showed no significant difference between the two groups, with and without persistent WBC excretion (p >0.05). Discussion: Persistent leukocyte excretion did not affect weight gain, consistent with reports that inflammatory stool markers have limited predictive value in allergic proctocolitis. Future studies with larger samples and refined inflammatory biomarkers are needed to clarify the clinical significance and potential long-term allergic implications of persistent intestinal inflammation. Conclusion: Persistent WBC excretion in children with allergic proctocolitis was observed in some of the patients, but was not associated with impaired weight gain during the first year of life.
- 20 April 2026
- Published by Maad Rayan Publishing Company in Journal of Shahrekord University of Medical Sciences
- Vol. 28 (1) , 14-22
A Case-Control Study of Detection of the Potentially Pathogenic Acanthamoeba Strains From the Oral Cavity of Diabetic Patients, Cancer Patients, and Healthy Individuals in Iran
Background and aims: Acanthamoeba is a genus of free-living amoebae (FLA) that can cause granulomatous amoebic encephalitis and amoebic keratitis. This study aimed to identify Acanthamoeba strains among diabetic and cancer patients and healthy individuals. Methods: In this cross-sectional study, 324 sterile cotton swab samples were collected from the oral cavity of 108 diabetic patients, 106 cancer patients undergoing chemotherapy, and 110 healthy individuals from June to October 2018 in Shahrekord, Iran. Samples were cultured onto 1.5% non-nutrient agar, and the Acanthamoeba spp. were investigated with morphological, molecular (polymerase chain reaction targeting 18SrRNA), and pathogenicity assays. Results: FLA was found in 130/324 (40.1%) oral cavity samples of individuals. Microscopic results using Giemsa staining revealed that 14/37 (37.8%) and 31/93 (33.3%) FLA isolated from healthy individuals and immunocompromised patients were identified as Acanthamoeba spp. Moreover, the PCR confirmed the existence of Acanthamoeba spp. in 4.7% of patients and 3.6% of controls. In addition, the PCR demonstrated that Acanthamoeba spp. were isolated in 6.6%, 8.2%, and 6.3% of cancer patients, diabetic patients, and healthy individuals, respectively. According to the sequence analysis of PCR products of 18S rRNA, the T4 (10 isolates) and T5 (3 isolates) genotypes of Acanthamoeba were identified in two groups. Finally, nine isolates genotyped as T4 were positive for potential pathogenic assays. Conclusion: The presence of the potentially pathogenic Acanthamoeba T4 genotype in both immunocompromised patients and healthy individuals indicated that it may pose a risk factor for immunocompromised individuals.
- 20 April 2026
- Published by Maad Rayan Publishing Company in Journal of Shahrekord University of Medical Sciences
- Vol. 28 (1) , 14-22
A Case-Control Study of Detection of the Potentially Pathogenic Acanthamoeba Strains From the Oral Cavity of Diabetic Patients, Cancer Patients, and Healthy Individuals in Iran
Background and aims: Acanthamoeba is a genus of free-living amoebae (FLA) that can cause granulomatous amoebic encephalitis and amoebic keratitis. This study aimed to identify Acanthamoeba strains among diabetic and cancer patients and healthy individuals. Methods: In this cross-sectional study, 324 sterile cotton swab samples were collected from the oral cavity of 108 diabetic patients, 106 cancer patients undergoing chemotherapy, and 110 healthy individuals from June to October 2018 in Shahrekord, Iran. Samples were cultured onto 1.5% non-nutrient agar, and the Acanthamoeba spp. were investigated with morphological, molecular (polymerase chain reaction targeting 18SrRNA), and pathogenicity assays. Results: FLA was found in 130/324 (40.1%) oral cavity samples of individuals. Microscopic results using Giemsa staining revealed that 14/37 (37.8%) and 31/93 (33.3%) FLA isolated from healthy individuals and immunocompromised patients were identified as Acanthamoeba spp. Moreover, the PCR confirmed the existence of Acanthamoeba spp. in 4.7% of patients and 3.6% of controls. In addition, the PCR demonstrated that Acanthamoeba spp. were isolated in 6.6%, 8.2%, and 6.3% of cancer patients, diabetic patients, and healthy individuals, respectively. According to the sequence analysis of PCR products of 18S rRNA, the T4 (10 isolates) and T5 (3 isolates) genotypes of Acanthamoeba were identified in two groups. Finally, nine isolates genotyped as T4 were positive for potential pathogenic assays. Conclusion: The presence of the potentially pathogenic Acanthamoeba T4 genotype in both immunocompromised patients and healthy individuals indicated that it may pose a risk factor for immunocompromised individuals.
- 25 October 2025
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
- Vol. 12 (1) , e43990
Clinical outcomes of infliximab treatment in hospitalized patients with severe COVID-19; a parallel, double-blind, randomized controlled trial
Introduction: This study aims to assess the effectiveness and safety of infliximab in hospitalized patients with severe COVID-19. Patients and Methods: This double blind, randomized controlled trial was conducted on 48 patients with COVID-19 at Hajar hospital in Shahrekord, Iran, from December 2020 to June 2021, to evaluate the efficacy and safety of infliximab in hospitalized patients with severe COVID-19. Eligible adults with confirmed severe COVID-19 were randomized to receive a single intravenous dose of infliximab (4 mg/kg) plus standard care (infliximab-treated group n = 24), or the control group (n = 24) received standard care alone. Data on demographics, clinical signs, radiologic findings, laboratory markers, and clinical outcomes were systematically collected at admission and during hospitalization. The primary outcomes included comparison of duration of hospital stay, mortality rate, mechanical ventilation requirement, and laboratory parameters between the two groups. Results: The results indicate that infliximab treatment in patients was associated with better clinical outcomes, including reduced hospital stay, lower mortality rates, decreased need for mechanical ventilation, and experiencing of better oxygen saturation. Laboratory parameters showed that the infliximab group experienced improved immune cell profiles marked by increased lymphocytes and decreased neutrophils and white blood cells. Additionally, inflammatory and coagulation markers such as D-dimer, lactate dehydrogenase (LDH), and C-reactive protein (CRP) were more effectively reduced in the infliximab-treated group, reflecting better control of inflammation; however, infliximab treatment indicated no significant difference in platelet levels between groups. Conclusion: Infliximab treatment in COVID-19 patients is associated with improved clinical outcomes, highlighting its potential as an effective immunomodulatory therapy. Trial Registration: The trial protocol was approved by the Iranian Registry of Clinical Trials (identifier: IRCT20201229049873N1; https://irct.behdasht.gov.ir/trial/53791), and ethical code from Shahrekord University of Medical Sciences (IR.SKUMS.REC.1399.227; https://ethics.research.ac.ir/EthicsProposalView.php?id=169921).
- 25 October 2025
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
- Vol. 12 (1) , e43990
Clinical outcomes of infliximab treatment in hospitalized patients with severe COVID-19; a parallel, double-blind, randomized controlled trial
Introduction: This study aims to assess the effectiveness and safety of infliximab in hospitalized patients with severe COVID-19. Patients and Methods: This double blind, randomized controlled trial was conducted on 48 patients with COVID-19 at Hajar hospital in Shahrekord, Iran, from December 2020 to June 2021, to evaluate the efficacy and safety of infliximab in hospitalized patients with severe COVID-19. Eligible adults with confirmed severe COVID-19 were randomized to receive a single intravenous dose of infliximab (4 mg/kg) plus standard care (infliximab-treated group n = 24), or the control group (n = 24) received standard care alone. Data on demographics, clinical signs, radiologic findings, laboratory markers, and clinical outcomes were systematically collected at admission and during hospitalization. The primary outcomes included comparison of duration of hospital stay, mortality rate, mechanical ventilation requirement, and laboratory parameters between the two groups. Results: The results indicate that infliximab treatment in patients was associated with better clinical outcomes, including reduced hospital stay, lower mortality rates, decreased need for mechanical ventilation, and experiencing of better oxygen saturation. Laboratory parameters showed that the infliximab group experienced improved immune cell profiles marked by increased lymphocytes and decreased neutrophils and white blood cells. Additionally, inflammatory and coagulation markers such as D-dimer, lactate dehydrogenase (LDH), and C-reactive protein (CRP) were more effectively reduced in the infliximab-treated group, reflecting better control of inflammation; however, infliximab treatment indicated no significant difference in platelet levels between groups. Conclusion: Infliximab treatment in COVID-19 patients is associated with improved clinical outcomes, highlighting its potential as an effective immunomodulatory therapy. Trial Registration: The trial protocol was approved by the Iranian Registry of Clinical Trials (identifier: IRCT20201229049873N1; https://irct.behdasht.gov.ir/trial/53791), and ethical code from Shahrekord University of Medical Sciences (IR.SKUMS.REC.1399.227; https://ethics.research.ac.ir/EthicsProposalView.php?id=169921).
- 29 June 2025
- Published by Maad Rayan Publishing Company in Journal of Shahrekord University of Medical Sciences
- Vol. 27 (2) , 55-59
Etiological evaluation of congenital hypothyroidism in children over three years old in Chaharmahal and Bakhtiari province, Iran
Background and aims: The etiology of congenital hypothyroidism (CH) is important in determining its severity, prognosis, genetic counseling, and clinical management. The present study was performed to investigate the etiology of CH in children in Chaharmahal and Bakhtiari. Methods: Screened children over the age of 3 years for hypothyroidism in the province were enrolled in this cross-sectional study. Then, in the case of permanent CH in the patient, demographic and laboratory findings, including thyroid-stimulating hormone (TSH) in primary screening, primary serum TSH, TSH after discontinuation of treatment, and age at the start of medication, were investigated, and patients were radiologically examined. The data were analyzed by SPSS 18 using descriptive statistics, a one-sample t-test, and a Chi-square test. Results: Dyshormonogenesis accounted for the most etiological percentage of the disease (72%), followed by dysgenesis (28%). Gender was significantly associated with etiology (P=0.022). Thus, dyshormonogenesis was more common in boys. The weight (P=0.564) and length at birth (P=0.978), maternal age (P=0.306), age at the beginning of medication (P=0.185), primary filter TSH (P=0.267), primary serum TSH (P=0.344), and TSH after discontinuation of medication (P=0.371) were not significantly associated with etiological factors. Conclusion: Among the etiological factors of CH, dyshormonogenesis was the most common cause among children in Chaharmahal and Bakhtiari province.
- 29 June 2025
- Published by Maad Rayan Publishing Company in Journal of Shahrekord University of Medical Sciences
- Vol. 27 (2) , 55-59
Etiological evaluation of congenital hypothyroidism in children over three years old in Chaharmahal and Bakhtiari province, Iran
Background and aims: The etiology of congenital hypothyroidism (CH) is important in determining its severity, prognosis, genetic counseling, and clinical management. The present study was performed to investigate the etiology of CH in children in Chaharmahal and Bakhtiari. Methods: Screened children over the age of 3 years for hypothyroidism in the province were enrolled in this cross-sectional study. Then, in the case of permanent CH in the patient, demographic and laboratory findings, including thyroid-stimulating hormone (TSH) in primary screening, primary serum TSH, TSH after discontinuation of treatment, and age at the start of medication, were investigated, and patients were radiologically examined. The data were analyzed by SPSS 18 using descriptive statistics, a one-sample t-test, and a Chi-square test. Results: Dyshormonogenesis accounted for the most etiological percentage of the disease (72%), followed by dysgenesis (28%). Gender was significantly associated with etiology (P=0.022). Thus, dyshormonogenesis was more common in boys. The weight (P=0.564) and length at birth (P=0.978), maternal age (P=0.306), age at the beginning of medication (P=0.185), primary filter TSH (P=0.267), primary serum TSH (P=0.344), and TSH after discontinuation of medication (P=0.371) were not significantly associated with etiological factors. Conclusion: Among the etiological factors of CH, dyshormonogenesis was the most common cause among children in Chaharmahal and Bakhtiari province.
- Open Access
- 19 May 2025
- Published by Brieflands in Health Scope
- Vol. 14 (2)
Development and Validation of a Colorectal Cancer Screening Determinants Tool Using Protection Motivation Theory
Background: Colorectal cancer (CRC) is one of the most common causes of cancer-related illness and death worldwide. Early detection of CRC through screening improves outcomes and decreases mortality; however, screening is still underutilized. While numerous factors influencing screening behaviors have been identified, no well-validated tools currently exist to fully explore these influences. The development of a valid and reliable assessment tool could clarify the factors that discourage or encourage people to undergo CRC screening, with the potential to increase participation rates. Objectives: The present study aimed to develop and validate a psychometrically sound colorectal cancer screening determinants tool (CCSDT) for people aged 50 - 70, based on the protection motivation theory (PMT). Methods: The cross-sectional study was conducted among people aged 50 - 69 from the Chaharmahal and Bakhtiari region of Iran, between July 15 and August 21, 2023. The total sample size was 500 people, with 250 participants used for exploratory factor analysis (EFA) and another 250 for confirmatory factor analysis (CFA) evaluation. A pool of 58 items was created through a literature review and discussions within the research group. The tool’s validity (face, content, construct, convergent, and divergent validity) and reliability (test-retest and internal consistency) were assessed. Results: Qualitative and quantitative methods ensured that the items were clear, relevant, and unambiguous (face validity). All items had an IS above 1.5. Content validity was confirmed through a high content validity ratio (CVR > 0.62) for all items, expert review, and a satisfactory modified Kappa coefficient (K* > 0.75). The EFA identified eight distinct factors [Kaiser-Meyer-Olkin (KMO) = 0.92, Bartlett’s test = 6674.18, P < 0.001] explaining a significant portion of the variance (over 57%). In this step, two items (factor 8: Q1 and Q2) were removed due to cross-loading. The 56-item tool was entered into CFA. The CFA with adjustments [Comparative Fit Index (CFI) = 0.94, Parsimonious Normed Fit Index (PNFI) = 0.67, discrepancy divided by degrees of freedom (CMIN/DF) = 2.22, root mean square error of approximation (RMSEA) = 0.08, and Incremental Fit Index (IFI) = 0.92] established a good model fit. Both convergent and divergent validity were supported by metrics such as average variance extracted (AVE), maximum shared squared variance (MSV), and composite reliability (CR). Cronbach’s alpha and McDonald’s omega were excellent (above 0.80). Test-retest analysis revealed good to moderate external reliability for different factors, indicating that scores remained consistent over time (perceived reward: r = 0.826, n = 30, P < 0.001; fear: r = 0.912, n = 30, P < 0.001; perceived sensitivity: r = 0.923, n = 30, P < 0.001; response cost: r = 0.826, n = 30, P < 0.001; and protection motivation: r = 0.917, n = 30, P < 0.001). Conclusions: This study validated the Persian version of the CCSDT, based on the PMT framework, in individuals aged 50 - 69, confirming its reliability and validity. The tool can help public health practitioners identify barriers to CRC screening and design targeted interventions to improve participation. These findings could contribute to reducing the CRC burden in Iran. Future research should validate the CCSDT in other populations and settings and explore its role in enhancing screening programs.
- 19 May 2025
- Published by Brieflands in Health Scope
- Vol. 14 (2)
Open AccessDevelopment and Validation of a Colorectal Cancer Screening Determinants Tool Using Protection Motivation Theory
Background: Colorectal cancer (CRC) is one of the most common causes of cancer-related illness and death worldwide. Early detection of CRC through screening improves outcomes and decreases mortality; however, screening is still underutilized. While numerous factors influencing screening behaviors have been identified, no well-validated tools currently exist to fully explore these influences. The development of a valid and reliable assessment tool could clarify the factors that discourage or encourage people to undergo CRC screening, with the potential to increase participation rates. Objectives: The present study aimed to develop and validate a psychometrically sound colorectal cancer screening determinants tool (CCSDT) for people aged 50 - 70, based on the protection motivation theory (PMT). Methods: The cross-sectional study was conducted among people aged 50 - 69 from the Chaharmahal and Bakhtiari region of Iran, between July 15 and August 21, 2023. The total sample size was 500 people, with 250 participants used for exploratory factor analysis (EFA) and another 250 for confirmatory factor analysis (CFA) evaluation. A pool of 58 items was created through a literature review and discussions within the research group. The tool’s validity (face, content, construct, convergent, and divergent validity) and reliability (test-retest and internal consistency) were assessed. Results: Qualitative and quantitative methods ensured that the items were clear, relevant, and unambiguous (face validity). All items had an IS above 1.5. Content validity was confirmed through a high content validity ratio (CVR > 0.62) for all items, expert review, and a satisfactory modified Kappa coefficient (K* > 0.75). The EFA identified eight distinct factors [Kaiser-Meyer-Olkin (KMO) = 0.92, Bartlett’s test = 6674.18, P < 0.001] explaining a significant portion of the variance (over 57%). In this step, two items (factor 8: Q1 and Q2) were removed due to cross-loading. The 56-item tool was entered into CFA. The CFA with adjustments [Comparative Fit Index (CFI) = 0.94, Parsimonious Normed Fit Index (PNFI) = 0.67, discrepancy divided by degrees of freedom (CMIN/DF) = 2.22, root mean square error of approximation (RMSEA) = 0.08, and Incremental Fit Index (IFI) = 0.92] established a good model fit. Both convergent and divergent validity were supported by metrics such as average variance extracted (AVE), maximum shared squared variance (MSV), and composite reliability (CR). Cronbach’s alpha and McDonald’s omega were excellent (above 0.80). Test-retest analysis revealed good to moderate external reliability for different factors, indicating that scores remained consistent over time (perceived reward: r = 0.826, n = 30, P < 0.001; fear: r = 0.912, n = 30, P < 0.001; perceived sensitivity: r = 0.923, n = 30, P < 0.001; response cost: r = 0.826, n = 30, P < 0.001; and protection motivation: r = 0.917, n = 30, P < 0.001). Conclusions: This study validated the Persian version of the CCSDT, based on the PMT framework, in individuals aged 50 - 69, confirming its reliability and validity. The tool can help public health practitioners identify barriers to CRC screening and design targeted interventions to improve participation. These findings could contribute to reducing the CRC burden in Iran. Future research should validate the CCSDT in other populations and settings and explore its role in enhancing screening programs.